FierceBiotech February 23, 2026 iRegene Hits Dual Global Firsts: U.S. Patient Dosed in Phase IIa for NouvNeu001 in Parkinson’s and First Enrollment in China’s Randomized MSA Trial for NouvNeu004 This article's full content could not be retrieved due to source site restrictions. Read full story on FierceBiotech